EU guidance could jeopardise confidentiality, says industry, but consumers want more openness
This article was originally published in Scrip
Executive Summary
Draft European guidance on the kind of information that can be released from drug approval dossiers has received a predictably mixed response from pharmaceutical industry and public interest bodies.